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Abstract
Post-translational modification of proteins with O-linked N-acetylglucosamine (O-GlcNAc) is linked the development of
diabetic cardiomyopathy. We investigated whether Nkx2.5 protein, a cardiac transcription factor, is regulated by O-GlcNAc.
Recombinant Nkx2.5 (myc-Nkx2.5) proteins were reduced by treatment with the O-GlcNAcase inhibitors STZ and O-(2-
acetamido-2-deoxy-D-glucopyroanosylidene)-amino-N-phenylcarbamate; PUGNAC) as well as the overexpression of
recombinant O-GlcNAc transferase (OGT-flag). Co-immunoprecipitation analysis revealed that myc-Nkx2.5 and OGT-flag
proteins interacted and myc-Nkx2.5 proteins were modified by O-GlcNAc. In addition, Nkx2.5 proteins were reduced in the
heart tissue of streptozotocin (STZ)-induced diabetic mice and O-GlcNAc modification of Nkx2.5 protein increased in
diabetic heart tissue compared with non-diabetic heart. Thus, excessive O-GlcNAcylation causes downregulation of Nkx2.5,
which may be an underlying contributing factor for the development of diabetic cardiomyopathy.
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Introduction
Cyclical post-translational modification of proteins with O-
linked N-acetylglucosamine (O-GlcNAc) is tightly regulated by the
juxtaposed actions of O-GlcNAc transferase (OGT) and O-
GlcNAc-selective N-acetylglucosaminidase (O-GlcNAcase), and
serves as a nutrient and stress sensor [1,2]. There exists a
reciprocal relation between O-GlcNAcylation and phosphorylation
on protein serine or threonine residues in regulating protein
functions and stability [3]. O-GlcNAcylation affects protein–
protein interactions, protein activity and stability [4–7].
Glycosylation with O-GlcNAc contributes to the etiology of
diverse diseases including diabetes. In diabetic patients, the
development of cardiomyopathy is attributable to hyperglycemia
and increased modification of proteins with O-GlcNAc [8–11].
The mechanisms linking O-GlcNAcylation to cardiomyopathy are
not known well.
Nkx2.5 is a homeobox-containing cardiac transcription factor
that is highly expressed by cardiomyocytes and has well-
established roles in cardiac development and disease [12–16].
We previously reported that excessive O-GlcNAcylation impairs
the differentiation of Nkx2.5/GFP-knock-in ES cells into cardiac
cells [17], implying that Nkx2.5 proteins were regulated by O-
GlcNAc during cardiogenesis. Little is know about the Nkx2.5
protein function and stability by post-translational modification. It
is reported that phosphorylation of Nlx2.5 protein by casein kinase
II increased activity through increased DNA binding [18].
Recently, Small ubiquitin-like modifiers (SUMO) conjugation
stabilized the formation of Nkx2.5-containing complexes and
enhanced transcriptional activity of Nkx2.5 proteins [19]. How-
ever, glycosylation of Nkx2.5 protein with O-GlcNAc has not been
reported.
Here, we investigated whether Nkx2.5 proteins post-transla-
tionally were modified by O-GlcNAc and the influence of the O-
GlcNAc modification on Nkx2.5 stability in cells treated with O-
GlcNAcase inhibitors (STZ and O-(2-acetamido-2-deoxy-D-glu-
copyroanosylidene)-amino-N-phenylcarbamate; PUGNAC) or the
overexpression of OGT as well as STZ-induced diabetic heat
tissues.
Results
Nkx2.5 Protein Decreased in the Heart Tissue of STZ-
induced Diabetic Mice
We investigated the levels of Nkx2.5 proteins in heart tissue
isolated from diabetic mice and non-diabetic mice. Nkx2.5 protein
levels were assessed by immunoblotting of homogenated diabetic
heart tissue collected 5 weeks after treatment with STZ. In diabetic
heart tissue, O-GlcNAcylation of proteins was higher while Nkx2.5
protein levels were lower than in non-diabetic heart tissue (Fig. 1A
and B).
Nkx2.5 Protein was Decreased by Treatment with O-
GlcNacase Inhibitor STZ or PUGNAc
We investigated the effect of the O-GlcNAcase inhibitors, STZ
and PUGNAC, on myc-Nkx2.5 protein levels in HEK293 cells.
Immunoblotting analysis revealed that treatment with STZ
(3 mM) for 24 hours remarkably increased the level of general
protein O-GlcNAcylation, but significantly decreased the expres-
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assessed the expression level of myc-Nkx2.5 in the presence of
STZ by immunofluorescence. Myc-Nkx2.5 was detected in the
nuclei of cells and at reduced levels in STZ-treated cells (data not
shown). The other O-GlcNAcase inhibitor, PUGNAc increased
the O-GlcNAcylation dose-dependently but also significantly
decreased the expression of myc-Nkx2.5 (Fig. 2C and D,
p,0.05).
Nkx2.5 Interacted with OGT Proteins and was Modified
by O-GlcNAc
To determine if excessive O-GlcNAcylation induced by OGT
overexpression could reduce Nkx2.5 expression, OGT-flag and
myc-Nkx2.5 genes was co-transfected into HEK293 cells and
immunoblotting was performed. Myc-Nkx2.5 levels were signifi-
cantly lower in HEK293 cells co-transfected with OGT-flag
(Fig. 3A and B, p,0.05). The interaction of myc-Nkx2.5 protein
and OGT-flag protein was assessed by co-immunoprecipitation.
As shown in figure 3C and D, co-immunoprecipitation analysis
demonstrated that myc-Nkx2.5 protein interacted with OGT-flag
protein.
We further investigated whether the interaction of Nkx2.5
protein with OGT protein can directly induce O-GlcNAcylation of
myc-Nkx2.5. After immunoprecipitation of myc-Nkx2.5 proteins
with antibody for myc, immunoblotting for O-GlcNAc was
performed with CTD110.6 and RL-2 antibodies. We found that
myc-Nkx2.5 protein was gylcocsylated with O-GlcNAc (Fig. 4A).
Next, we determined if Nkx2.5 protein of heart tissues is modified
with O-GlcNAc. Heart homogenates were subjected to immuno-
precipitation with anti-Nkx2.5 antibody, followed by immuno-
blotting with anti-O-GlcNAc antibodies, RL-2. STZ-induced
diabetic mice with glucose levels of greater than 400 mg/dL at
3 and 7 days post-injection were used. Nkx2.5 proteins were
modified with O-GlcNAc and this modification in Nkx2.5 proteins
was increased in diabetic heart compared with control heart
(Fig. 4B).
Discussion
Elevated O-GlcNAcylation has been implicated in the develop-
ment of diabetic cardiomyopathy [2,9,11,20]. While the contrib-
uting mechanism is not clear, O-GlcNAcylation modification of
cardiac myofilament proteins (MLC2 and TnI) may modulate
myocardial contractile function, and chronic exposure to elevated
O-GlcNAcylation may impair cardiac function in diabetic patients
[21]. Moreover, elevated O-GlcNAcylation induces collagen
expression, which results in diabetic cardiomyopathy accompany-
ing by myocardial fibrosis [22]. Here we show that the induction
of Nkx2.5 downregulation in response to O-GlcNAcylation
conditions may be an additional diabetic cardiomyopathy
mechanism and possibly interfere with cardiomyocyte survival
pathways.
Nkx2.5 is essential for embryonic cardiogenesis, abundantly
expressed in the adult heart, and required for homeostasis and
survival of cardiac myocytes in the adult heart [12–14,16,23]. The
transgenic mice that overexpress a dominant negative mutant of
Nkx2–5 showed degeneration of cardiac myocytes and impair-
ment of cardiac function in adult heart, and Nkx2.5 was critical for
maintaining a highly differentiated cardiac phenotype and for
protecting the heart from stresses [23].
Relatively little is known about the post-translational regulation
of Nkx2.5 protein. On serine 163 of Nkx2.5 protein is
phosphorylated by casein kinase II, which is involved in nuclear
localization and transcriptional activity of Nkx2.5 protein [18]. We
previously demonstrated that the differentiation of Nkx2.5-lineage
cardiomyocyte precursor cells from ES cells was suppressed in
excessive O-GlcNAcylation conditions [17].
The modification of Nkx2.5 proteins with O-GlcNAc as well as
the role O-GlcNAc in the function of Nkx2.5 proteins was not
known. To understand the role of O-GlcNAc in post-translational
regulation of Nkx2.5, it would be important to extend such an
approach to cultured adult cardiac myocytes. However, the
limitations involved with adult cardiac myocytes are the absence of
mitosis and possibility of these cells to proliferate and therefore
procurement of a large quantity of cells is almost impossible to
study compared the drug effect on O-GlcNAcylation in cardio-
myocytes isolated from the same individual. In the present study,
we showed that Nkx2.5 proteins were modified with O-GlcNAc
and the excessive O-GlcNAcylation conditions result in the
downregulation of Nkx2.5 protein. This effect was detectable in
transfected HEK293 cells and in the heart tissues of STZ-induced
diabetic mice with glucose levels of greater than 400 mg/dL.
Figure 1. Expression of Nkx2.5 in the heart tissue of diabetic mice (DM). (A) Immunoblotting analysis of Nkx2.5 and O-GlycNAcylated
proteins in the heart tissue of DM intraperitoneally injected with streptozotocine (180 mg/kg body weight). (B) Graphs showed relative O-GlcNAc
(left) and Nkx2.5 (right) levels normalized to the tubulin levels in DM and control. Nkx2.5 protein in diabetic heart of mice was significantly decreased.
O-GlcNAcylation and Nkx2.5 protein levels were compared in DM vs control. All values are presented as the mean6standard error of three
independent experiments. *p,0.05 DM vs. control.
doi:10.1371/journal.pone.0038053.g001
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tial sites in a protein on which phosphorylation and O-
GlcNAcylation compete with one another for the same site.
According to results obtained from YinOYang 1.2, there were 13
sites in Nxk2.5 predicted as potential Yin Yang sites (having same
serine/threonine residues for both phosphorylation and O-
GlcNAcylation). We suggest that excessive O-GlcNAcyation in
Nkx2.5 protein may alter its stability via the ‘‘Ying-Yang
hypothesis’’ whereby O-GlcNAcylation may be competitive or
reciprocal to phosphorylation, which can lead to a decrease in
Nkx2.5 protein level.
Critical goals of future studies are to define the regulatory
pathways that control the downregulation of Nkx2.5 in response to
excessive O-GlcNAcylation and the pathways downstream of
Nkx2.5 that are required for cardiomyocyte development and
function.
Materials and Methods
Reagents and Antibodies
STZ and PUGNAc for inhibiting O-GlcNAcase were pur-
chased from Sigma (St Louis, MO) and Toronto Research
Chemicals (North York, Ontario, Canada). The plasmid
Figure 2. Reduction of myc-Nkx2.5 protein in cells treated with O-GlcNAcase inhibotirs. (A) Immunoblotting of myc-Nkx2.5 and O-
GlycNAcylated proteins in myc-Nkx2.5-transfected HEK293 cells in the presence or absence of 3 mM streptozotocine (STZ). (B) Graphs showed relative
O-GlcNAc (left) and myc-Nkx2.5 (right) levels normalized to the tubulin levels in STZ-treated and untreated cells. O-GlcNAcylation levels were
compared in untreated cells vs STZ-treated cells and untreated myc-Nkx2.5 cells vs STZ-treated myc-Nkx2.5 cells. The myc-Nkx2.5 protein levels were
compared in untreated myc-Nkx2.5 cells vs STZ-treated myc-Nkx2.5 cells. All values are presented as the mean6standard error of three independent
experiments. *p,0.05. (C) Immunoblotting analysis of myc-Nkx2.5 and O-GlycNAcylated proteins in myc-Nkx2.5-transduced HEK293 cells in the
presence or absence of O-(2-acetamido-2-deoxy-D-glucopyroanosylidene)-amino-N-phenylcarbamate (10 or 100 mM PUGNAC). (D) Graphs showed
relative O-GlcNAc (left) and myc-Nkx2.5 (right) levels normalized to the tubulin levels in PUGNAC-treated and untreated cells. The treatment with STZ
and PUGNAC significantly increased the O-GlcNAcylation of intracellular proteins, but decreased the myc-Nkx2.5 protein significantly. O-
GlcNAcylation levels were compared in untreated myc-Nkx2.5 cells vs PUGNAC-treated myc-Nkx2.5 cells. The myc-Nkx2.5 protein levels were
compared in untreated myc-Nkx2.5 cells vs PUGNAC treated myc-Nkx2.5 cells. All values are presented as the mean6standard error of three
independent experiments. *p,0.05.
doi:10.1371/journal.pone.0038053.g002
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provided by Dr. Hidaka (National Cardiovascular Research
Institute, Osaka, Japan). The plasmid expressing recombinant
human OGT (OGT-flag) was provided by Dr. Cho (Yeonsei
University, Seoul, Korea). Antibodies against Nkx2.5, myc, and
tubulin were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). The antibodies CTD110.6 and RL-2 for O-GlcNAc
detection was purchased from Covance (Princeton, NJ) and
Figure 3. Interaction of Nkx2.5 and O-GlcNAc transferase (OGT). (A) Immunoblotting analysis of myc-Nkx2.5 and O-GlycNAcylated proteins in
myc-Nkx2.5 and OGT-flag-co-transfected HEK293 cells. (B) Graphs showed relative O-GlcNAc (left) and myc-Nkx2.5 (right) levels normalized to the
tubulin levels in co-transfected cells and single transfected cells. O-GlcNAcylation levels were compared in no-transfected cells vs OGT-flag cells and
myc-Nkx2.5 cells vs OGT-flag/myc-Nkx2.5 cells. Myc-Nkx2.5 protein levels were compared in myc-Nkx2.5 cells vs OGT-flag/myc-Nkx2.5 cells. All values
are presented as the mean6standard error of three independent experiments. *p,0.05. (C) After immunoprecipitation with antibodies specific for
Nkx2.5 and flag, immunoblotting with antibodies for myc, flag, and OGT was performed. (D) After immunoprecipitation with antibodies specific for
OGT, immunoblotting with antibodies for myc, flag, and OGT was performed. The interaction between myc-Nkx2.5 and OGT-flag was observed.
doi:10.1371/journal.pone.0038053.g003
Figure 4. Modification of Nkx2.5 by O-GlcNAc. (A) The lysates of myc-Nkx2.5 and OGT-flag-co-transfected HEK293 cells were subjected to
immunoprecipitation with anti-myc antibody and immunoblottings were performed with antibodies against O-GlcNAc (CTD110.6, RL-2) and myc. The
modification of myc-Nkx2.5 with O-GlcNAc was detected. (B) Diabetic mice (DM) maintained elevated blood glucose level (.430 mg/dL) at 3 and 7
days after injection with streptozotocine (180 mg/kg body weight). The heart homogenates of control and diabetic mice were immunoprecipitated
with anti-Nkx2.5 antibody, followed by immunoblottings with RL-2 antibodies against O-GlcNAc and anti-Nkx2.5 antibody. Nkx2.5 proteins of heart
tissues were modified with O-GlcNAc and this modification increased in diabetic mice compared with control mice.
doi:10.1371/journal.pone.0038053.g004
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OGT and FLAG were purchased from Sigma.
Transfection with Myc-Nkx2.5 and OGT-flag Plasmid
Human embryonic kidney (HEK293) cells were obtained from
the American Type Culture Collection (ATCC, Rockville, MD).
HEK293 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Life Technologies, Invitrogen, Cergy Pontoise,
France) supplemented with 10% fetal bovine serum (FBS) (v/v),
2 mM L-glutamine, 5 IU/ml penicillin, and 50 mg/ml streptomy-
cin at 37uC in a humidified atmosphere enriched with 5% CO2.
HEK293 cells were treated with one of the following OGA
inhibitors STZ (1–3 mM) or PUGNAc (10–100 mM). HEK293
cells were transiently transfected with myc-Nkx2.5 or the OGT-
flag plasmids using Lipofectamine and Plus Reagent (Invitrogen).
Myc-Nkx2.5 and OGT-flag expression was confirmed by immu-
noprecipitation and immunoblotting.
Immunoblotting
HEK293 cells were washed with cold phosphate-buffered saline
(PBS), and then lysed in lysis buffer containing a protease inhibitor
mixture (0.1 mM phenylmethylsulfonyl fluoride, 5 mg/ml aproti-
nin, 5 mg/ml pepstatin A, and 1 mg/ml chymostatin). Proteins
were separated by SDS-PAGE and transferred to nitrocellulose
membranes. The membrane was blocked with 5% nonfat dry milk
in Tris-buffered saline and then incubated with primary antibod-
ies. Blots were developed using peroxidase-conjugated secondary
antibodies and visualized with enhanced chemiluminescence
reagent (Amersham Biosciences, Buckinghamshire, UK) according
to the manufacturer’s recommendations.
Immunoprecipitation
For immunoprecipitation experiments, cell extracts and heart
homogenates were centrifuged at 20,000 g for 30 minutes at 4uC.
Aliquots of 500 mg proteins extracted cells and heart tissues were
incubated with mouse monoclonal anti-Nkx2.5, anti-OGT, anti-
flag, anti-myc or anti-O-GlcNAc antibodies at 4uC overnight.
Antibody-bound proteins were precipitated with 30 ml of A/G
protein-coupled sepharose beads for 124 hours at 4uC. Beads
were gently centrifuged for 1 minute and washed with lysis buffer.
Finally, 25250 ml of loading buffer was added and the beads
boiled at 952100uC for 5 minutes to denature the protein and
separate it from the protein-A/G beads. Immunoblotting of the
recovered protein was performed.
Immunofluorescence Staining
HEK293 cells were grown on 8-well chamber slides and washed
twice with cold PBS. Cells were fixed in 3% of paraformaldehyde
in cold PBS for 15 minutes, washed with PBS, and permeabilized
with 0.1% Triton X-100 for 5 minutes. Nonspecific sites were
blocked with goat serum. Fixed cells were then incubated for 60
minutes with anti-myc antibody and myc-Nkx2.5. Labeling was
visualized using FITC-conjugated secondary antibodies. Nuclei
were specifically stained with 49,69-diamidino-2-phenylindole
(DAPI). Images of stained cells were acquired with a fluorescence
microscopy (Leica, Wetzlar, Germany), equipped with a CCD
camera (Leica) using a green filter (excitation 488 nm, emission
520 nm).
Diabetic Mouse Model
C57BL/6 mice were supplied from the Center for Animal
Resource and Development, Seoul National University. The mice
used in this study, all between 4 and 20 weeks of age, were
maintained in individually ventilated cages (Thoren caging
systems, Hazleton, PA) at 2462uC and 5065% humidity with a
12 h/12 h (light/dark) cycle. Mice were given ad libitum access to
irradiated mouse feed (Purina Korea, Seoul, Korea) and reverse
osmosis water containing 2 ppm chloride. For diabetic mice,
seven-week-old male C57BL/6 mice were intraperitoneally
injected with 180 mg of STZ per kg of body weight. The blood
glucose levels of mice were measured daily, and mice with blood
glucose levels of 3002500 mg/dL were considered to be diabetic.
Collected heart tissues were homogenized in lysis buffer for
immunoblotting. Non-diabetic control heart tissue was obtained
age-matched male C57BL/6 mice.
Ethics Statement
Additionally, all animal experiments were conducted in the
Center for Animal Resource and Development. This research was
approved by the Institutional Animal Care and Use Committee
(IACUC) of Seoul National University (SNU-080828-2).
Statistical Analysis
Data are presented as the means6S.E.M. for at least three
independent experiments and statistically evaluated using AN-
OVA followed by the t-test. P-values less than 0.05 were
considered statistically significant.
Author Contributions
Conceived and designed the experiments: HSK. Performed the experi-
ments: HSK JSW HJJ. Analyzed the data: HSK JSW HJJ WKM.
Contributed reagents/materials/analysis tools: JSW HJJ WKM. Wrote the
paper: HSK.
References
1. Hunter T, Karin M (1992) The regulation of transcription by phosphorylation.
Cell 70: 375–387.
2. Hart GW, Housley MP, Slawson C (2007) Cycling of O-linked beta-N-
acetylglucosamine on nucleocytoplasmic proteins. Nature 446: 1017–1022.
3. Hart GW, Kreppel LK, Comer FI, Arnold CS, Snow DM, et al. (1996) O-
GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-
phosphorylation and putative roles in protein multimerization. Glycobiology 6:
711–716.
4. Kim HS, Kim EM, Lee J, Yang WH, Park TY, et al. (2006) Heat shock protein
60 modified with O-linked N-acetylglucosamine is involved in pancreatic beta-
cell death under hyperglycemic conditions. FEBS Lett 580: 2311–2316.
5. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, et al. (2006) Modification of p53
with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell
Biol 8: 1074–1083.
6. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, et al. (2003) O-GlcNAc
modification is an endogenous inhibitor of the proteasome. Cell 115: 715–725.
7. Guinez C, Mir AM, Dehennaut V, Cacan R, Harduin-Lepers A, et al. (2008)
Protein ubiquitination is modulated by O-GlcNAc glycosylation. FASEB J 22:
2901–2911.
8. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic
complications. Nature 414: 813–820.
9. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, et al. (2003)
Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium
cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278: 44230–
44237.
10. Hu Y, Belke D, Suarez J, Swanson E, Clark R, et al. (2005) Adenovirus-
mediated overexpression of O-GlcNAcase improves contractile function in the
diabetic heart. Circ Res 96: 1006–1013.
11. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, et al. (2001) Hyperglycemia
activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes
50: 2363–2375.
Nkx2.5 Modification by O-GlcNAc
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e3805312. Lints TJ, Parsons LM, Hartley L, Lyons I, Harvey RP (1993) Nkx-2.5: a novel
murine homeobox gene expressed in early heart progenitor cells and their
myogenic descendants. Development 119: 419–431.
13. Komuro I, Izumo S (1993) Csx: a murine homeobox-containing gene specifically
expressed in the developing heart. Proc Natl Acad Sci U S A 90: 8145–8149.
14. Hidaka K, Lee JK, Kim HS, Ihm CH, Iio A, et al. (2003) Chamber-specific
differentiation of Nkx2.5-positive cardiac precursor cells from murine embryonic
stem cells. FASEB J 17: 740–742.
15. Kasahara H, Lee B, Schott JJ, Benson DW, Seidman JG, et al. (2000) Loss of
function and inhibitory effects of human CSX/NKX2.5 homeoprotein
mutations associated with congenital heart disease. J Clin Invest 106: 299–308.
16. Akazawa H, Komuro I (2005) Cardiac transcription factor Csx/Nkx2–5: Its role
in cardiac development and diseases. Pharmacol Ther 107: 252–268.
17. Kim HS, Park SY, Choi YR, Kang JG, Joo HJ, et al. (2009) Excessive O-
GlcNAcylation of proteins suppresses spontaneous cardiogenesis in ES cells.
FEBS Lett 583: 2474–2478.
18. Kasahara H, Izumo S (1999) Identification of the in vivo casein kinase II
phosphorylation site within the homeodomain of the cardiac tisue-specifying
homeobox gene product Csx/Nkx2.5. Mol Cell Biol 19: 526–536.
19. Wang J, Zhang H, Iyer D, Feng XH, Schwartz RJ (2008) Regulation of cardiac
specific nkx2.5 gene activity by small ubiquitin-like modifier. J Biol Chem 283:
23235–23243.
20. McNulty PH (2007) Hexosamine biosynthetic pathway flux and cardiomyopathy
in type 2 diabetes mellitus. Focus on ‘‘Impact of type 2 diabetes and aging on
cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart’’.
Am J Physiol Cell Physiol 292: C1243–1244.
21. Ramirez-Correa GA, Jin W, Wang Z, Zhong X, Gao WD, et al. (2008) O-linked
GlcNAc modification of cardiac myofilament proteins: a novel regulator of
myocardial contractile function. Circ Res 103: 1354–1358.
22. Kohda Y, Kanematsu M, Kono T, Terasaki F, Tanaka T (2009) Protein O-
glycosylation induces collagen expression and contributes to diabetic cardiomy-
opathy in rat cardiac fibroblasts. J Pharmacol Sci 111: 446–450.
23. Toko H, Zhu W, Takimoto E, Shiojima I, Hiroi Y, et al. (2002) Csx/Nkx2–5 is
required for homeostasis and survival of cardiac myocytes in the adult heart.
J Biol Chem 277: 24735–24743.
Nkx2.5 Modification by O-GlcNAc
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38053